Obese female SHHF/Mcc-facp rats resist antihypertensive effects of renin-angiotensin system inhibition

Leslie C Sharkey, B. J. Holycross, S. A. McCune, M. J. Radin, M. Judith Radin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gender and obesity may influence response to pharmacological modulation of the renin-angiotensin system. We used SHHF/Mcc-facp rats to study effect of obesity and gender on the ability of an AT1 receptor antagonist to decrease blood pressure. After 2 weeks treatment with irbesartan (50 mg/kg), only lean and obese males showed significant decreases in blood pressure, while obese females were completely resistant. Lean females showed a trend toward lowering of pressure (p=0.06). However, irbesartan similarly shifted angiotensin II dose response curves to the right in all groups. Twelve weeks of irbesartan also failed to decrease blood pressure, but did significantly reduce heart weight in obese females. In untreated rats, obese females had lower plasma renin activity and serum angiotensin converting enzyme activity compared to lean males, while lean and obese females had increased urinary endothelin excretion. Despite an otherwise similar genetic background contributing to hypertension and heart failure, obese females have different patterns of humoral activation compared to lean males, which may contribute to their resistance to the depressor effects of irbesartan.

Original languageEnglish (US)
Pages (from-to)227-239
Number of pages13
JournalClinical and Experimental Hypertension
Volume23
Issue number3
DOIs
StatePublished - May 7 2001

Fingerprint

irbesartan
Renin-Angiotensin System
Antihypertensive Agents
Blood Pressure
Obesity
Endothelins
Peptidyl-Dipeptidase A
Renin
Angiotensin II
Heart Failure
Pharmacology
Hypertension
Pressure
Weights and Measures
Serum

Keywords

  • Angiotensin receptor blockers
  • Endothelin
  • Female
  • Hypertension
  • Obesity
  • Renin-angiotensin system
  • SHHF/Mcc-fa rats

Cite this

Obese female SHHF/Mcc-facp rats resist antihypertensive effects of renin-angiotensin system inhibition. / Sharkey, Leslie C; Holycross, B. J.; McCune, S. A.; Radin, M. J.; Radin, M. Judith.

In: Clinical and Experimental Hypertension, Vol. 23, No. 3, 07.05.2001, p. 227-239.

Research output: Contribution to journalArticle

Sharkey, Leslie C ; Holycross, B. J. ; McCune, S. A. ; Radin, M. J. ; Radin, M. Judith. / Obese female SHHF/Mcc-facp rats resist antihypertensive effects of renin-angiotensin system inhibition. In: Clinical and Experimental Hypertension. 2001 ; Vol. 23, No. 3. pp. 227-239.
@article{02eda14b8d2c416faeaefafd008c260b,
title = "Obese female SHHF/Mcc-facp rats resist antihypertensive effects of renin-angiotensin system inhibition",
abstract = "Gender and obesity may influence response to pharmacological modulation of the renin-angiotensin system. We used SHHF/Mcc-facp rats to study effect of obesity and gender on the ability of an AT1 receptor antagonist to decrease blood pressure. After 2 weeks treatment with irbesartan (50 mg/kg), only lean and obese males showed significant decreases in blood pressure, while obese females were completely resistant. Lean females showed a trend toward lowering of pressure (p=0.06). However, irbesartan similarly shifted angiotensin II dose response curves to the right in all groups. Twelve weeks of irbesartan also failed to decrease blood pressure, but did significantly reduce heart weight in obese females. In untreated rats, obese females had lower plasma renin activity and serum angiotensin converting enzyme activity compared to lean males, while lean and obese females had increased urinary endothelin excretion. Despite an otherwise similar genetic background contributing to hypertension and heart failure, obese females have different patterns of humoral activation compared to lean males, which may contribute to their resistance to the depressor effects of irbesartan.",
keywords = "Angiotensin receptor blockers, Endothelin, Female, Hypertension, Obesity, Renin-angiotensin system, SHHF/Mcc-fa rats",
author = "Sharkey, {Leslie C} and Holycross, {B. J.} and McCune, {S. A.} and Radin, {M. J.} and Radin, {M. Judith}",
year = "2001",
month = "5",
day = "7",
doi = "10.1081/CEH-100102662",
language = "English (US)",
volume = "23",
pages = "227--239",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Obese female SHHF/Mcc-facp rats resist antihypertensive effects of renin-angiotensin system inhibition

AU - Sharkey, Leslie C

AU - Holycross, B. J.

AU - McCune, S. A.

AU - Radin, M. J.

AU - Radin, M. Judith

PY - 2001/5/7

Y1 - 2001/5/7

N2 - Gender and obesity may influence response to pharmacological modulation of the renin-angiotensin system. We used SHHF/Mcc-facp rats to study effect of obesity and gender on the ability of an AT1 receptor antagonist to decrease blood pressure. After 2 weeks treatment with irbesartan (50 mg/kg), only lean and obese males showed significant decreases in blood pressure, while obese females were completely resistant. Lean females showed a trend toward lowering of pressure (p=0.06). However, irbesartan similarly shifted angiotensin II dose response curves to the right in all groups. Twelve weeks of irbesartan also failed to decrease blood pressure, but did significantly reduce heart weight in obese females. In untreated rats, obese females had lower plasma renin activity and serum angiotensin converting enzyme activity compared to lean males, while lean and obese females had increased urinary endothelin excretion. Despite an otherwise similar genetic background contributing to hypertension and heart failure, obese females have different patterns of humoral activation compared to lean males, which may contribute to their resistance to the depressor effects of irbesartan.

AB - Gender and obesity may influence response to pharmacological modulation of the renin-angiotensin system. We used SHHF/Mcc-facp rats to study effect of obesity and gender on the ability of an AT1 receptor antagonist to decrease blood pressure. After 2 weeks treatment with irbesartan (50 mg/kg), only lean and obese males showed significant decreases in blood pressure, while obese females were completely resistant. Lean females showed a trend toward lowering of pressure (p=0.06). However, irbesartan similarly shifted angiotensin II dose response curves to the right in all groups. Twelve weeks of irbesartan also failed to decrease blood pressure, but did significantly reduce heart weight in obese females. In untreated rats, obese females had lower plasma renin activity and serum angiotensin converting enzyme activity compared to lean males, while lean and obese females had increased urinary endothelin excretion. Despite an otherwise similar genetic background contributing to hypertension and heart failure, obese females have different patterns of humoral activation compared to lean males, which may contribute to their resistance to the depressor effects of irbesartan.

KW - Angiotensin receptor blockers

KW - Endothelin

KW - Female

KW - Hypertension

KW - Obesity

KW - Renin-angiotensin system

KW - SHHF/Mcc-fa rats

UR - http://www.scopus.com/inward/record.url?scp=0035029606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035029606&partnerID=8YFLogxK

U2 - 10.1081/CEH-100102662

DO - 10.1081/CEH-100102662

M3 - Article

C2 - 11339689

AN - SCOPUS:0035029606

VL - 23

SP - 227

EP - 239

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 3

ER -